DelSite Biotechnologies, Inc. Supplies Polymer for Novel Heart Repair Program

IRVING, Texas, Aug. 13 /PRNewswire-FirstCall/ -- Carrington Laboratories, Inc. today announced its DelSite Biotechnologies, Inc. subsidiary entered into a material transfer agreement to provide evaluation qualities of its GMP-grade high-molecular-weight GelSite polymer to a large U.S. company for testing a novel technique for cardiac tissue repair.

Among the key features of the GelSite(R) polymer are its mucoadhesive properties which, in this experimental application, may create a molecular anchor in order to slow or prevent the dispersion of active ingredients away from specific tissue. The technology enables controlled release of injected systemic drugs, and its mucoadhesive properties make it a very effective delivery vehicle for nasally administered powder-formulated vaccines.

The cardiac tissue application will test the polymer's injectability, gelation kinetics and cyto-compatibility with a variety of cell types. Further tests will access the material's thrombo-embolic potential. If in vitro tests are successful, the program will advance to small and large animal models, including efficacy evaluations in improving ventricular geometry and global heart function in post-myocardial infarction models.

"This evaluation program suggests a broader versatility for the DelSite polymer technology than was previously envisioned," commented Carlton E. Turner, PhD, CEO of Carrington. "It could be an exciting addition to the range of programs we are advancing in the areas of nasal vaccines and controlled release of systemic proteins and peptides."

About Carrington

Carrington Laboratories, Inc. is an ISO 9001-certified, research-based, biopharmaceutical and consumer products company currently utilizing naturally-occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care, as well as to manufacture and market the nutraceutical raw material Manapol(R) and cosmetic raw material Hydrapol(TM). Carrington also manufactures and markets consumer products and manufactures quality products for other companies. Manufacturing operations comply with cGMP standards. Carrington's DelSite Biotechnologies subsidiary is developing its proprietary GelSite(R) technology designed to provide controlled release of peptide and protein-based drugs. Carrington's technology is protected by more than 130 patents in 26 countries. Select products carry the CE mark, recognized by more than 20 countries around the world. For more information, visit http://www.carringtonlabs.com.

Certain statements in this release concerning Carrington may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to: subsequent changes in plans by the Company's management; delays or problems in formulation, manufacturing, distribution, production and/or launch of new finished products; changes in the regulatory process; changes in market trends; and a number of other factors and risks described from time to time in the Company's filings with the Securities & Exchange Commission, including the Form 10-Q, filed May 15, 2007.

Carrington Laboratories, Inc.

CONTACT: Carlton E. Turner, Chief Executive Officer of CarringtonLaboratories, Inc., +1-972-518-1300

Back to news